Subscribe To

Price Alert Latest News Economic Calendar News

ADXN / Addex Announces Upcoming Conferences it will participate for H1 2023

Geneva, Switzerland, March 16, 202 3 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the first half of 2023: Read More

Demo Live Account See Partner Details

Content Topics

Addex

Announces

Upcoming

Conferences

Will

Participate

2023

Stock

ADXN

Posted: Mar 16 2023, 02:00

Author Name: GlobeNewsWire

ADXN News

By GlobeNewsWire
September 6, 2023

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mo

By Seeking Alpha
August 10, 2023

Addex Therapeutics Ltd (ADXN) Q2 2023 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Offi

By GlobeNewsWire
August 4, 2023

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu

By Seeking Alpha
May 12, 2023

Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Call Transcript

Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive

By GlobeNewsWire
May 4, 2023

Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulat

By Seeking Alpha
March 31, 2023

Addex Therapeutics Ltd. (ADXN) Q4 2022 Earnings Call Transcript

Addex Therapeutics Ltd. (NASDAQ:ADXN ) Q4 2022 Results Conference Call March 30, 2023 10:00 AM ET Company Participants Timothy Dyer - CEO Robert Lutje

By GlobeNewsWire
March 28, 2023

Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

Geneva, Switzerland, March 2 8 , 20 2 3 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric m

By GlobeNewsWire
March 16, 2023

Addex Announces Upcoming Conferences it will participate for H1 2023

Geneva, Switzerland, March 16, 202 3 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering alloster

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.